AAS
ALNY icon

Ameritas Advisory Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ameritas Advisory Services’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-116
Closed -$52.9K – 955
2025
Q3 		$52.9K Sell
116
-12
-9% -$4.89K ﹤0.01% 1061
2025
Q2 		$41.7K Buy
+128
New +$35.4K ﹤0.01% 1392
2023
Q2 		– Sell
-4
Closed -$819 – 615
2023
Q1 		$819 Buy
+4
New +$841 ﹤0.01% 2581

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Ameritas Advisory Services's ALNY Position: Q4 2025 in Review

Ameritas Advisory Services sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 116 shares — an estimated $52.9K sold.

Ameritas Advisory Services first reported a position in ALNY in Q1 2023 and held it in 3 quarters. The position peaked at $52.9K in Q3 2025. 848 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Ameritas Advisory Services reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Ameritas Advisory Services sold 116 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $52.9K.
  • Ameritas Advisory Services first reported a position in Alnylam Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Ameritas Advisory Services's Alnylam Pharmaceuticals position peaked at $52.9K in Q3 2025.
  • 848 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Ameritas Advisory Services's 13F filing for Q4 2025, filed 4 Feb 2026.